Investor Presentation - November 2022
Celebrating 25 years of Continuous Growth and Improvement in Animal Health and Welfare
Dechra is a global specialist veterinary pharmaceuticals and related products business. Our expertise is in the development, manufacture, marketing and sales of high quality products exclusively for veterinarians worldwide.
Our Purpose is the sustainable improvement of global animal health and welfare.
Companion Animal Products (CAP)
Species: Dogs and cats.
Key therapeutic sectors: Endocrinology, dermatology, analgesia and anaesthesia, antibiotics, cardiovascular and critical care.
Food producing Animal Products (FAP)
Species: Poultry, pigs and an increasing presence in cattle.
Key therapeutic sectors: Water soluble antibiotics, poultry vaccines, locomotion (lameness) and pain management.
Equine
Species: Horses and ponies.
Key therapeutic sectors: Lameness, pain management and equine vaccines.
Nutrition
Species: Dogs and cats.
Key therapeutic sectors: Our pet diets are
available to support the wellbeing of cats and dogs with numerous therapeutic conditions including allergies, obesity, heart and kidney disease.
For more information please visit www.dechra.com
Dechra at a Glance
|
£682m |
75% |
~90 |
>2,300 |
|
Revenue |
Countries with |
Colleagues |
|
|
FY22 Revenue |
|||
|
from CAP |
market presence |
worldwide |
|
|
£174m |
8 |
~5,800 |
|
FY22 uEBIT |
Manufacturing sites |
Product registrations |
|
12% |
||
|
Revenue |
||
|
from FAP |
||
|
25.6% |
60/40 |
|
|
Revenue and uEBIT |
||
|
FY22 uEBIT margin |
||
|
split EU*/NA |
||
* EU segment includes Rest of the World
®
3
Celebrating 25 Years of Growth
Consistent revenue and profit growth through organic growth and targeted M&A activity
Revenue (£m)
|
800 |
9-year |
|||
|
CAGR* |
||||
|
700 |
||||
|
600 |
Revenue (LHS) |
+15% |
||
|
uEBIT (RHS) |
+18% |
Disposal of low margin |
||
|
services division (NVS) led |
|
|
500 |
to revenues decreasing |
|
but profit increased |
|
|
400 |
|
|
300 |
|
|
200 |
|
|
100 |
|
200 |
|
|
180 |
|
|
160 |
|
|
140 |
|
|
120 |
(£m) |
|
100 |
uEBIT |
80
60
40
20
|
0 |
0 |
* Since disposal of NVS
®
4
Strong Financial Track Record
Stable multi-year margin profile and attractive shareholder returns
% of Group revenue
Gross and operating margin
70%
60%
50%
40%
30%
20%
10%
0%
FY13 FY14 FY15 FY16 FY17 FY18 FY19 FY20 FY21 FY22
|
Gross Margin % |
uEBIT % |
|
Pence per share
EPS and DPS
140
120
100
80
60
40
20
0
FY13 FY14 FY15 FY16 FY17 FY18 FY19 FY20 FY21 FY22
EPS DPS
®
5
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
Disclaimer
Dechra Pharmaceuticals plc published this content on 28 November 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 28 November 2022 10:37:24 UTC.